

Bevacizumab				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
NCMAG123	Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first line treatment of adult patients with metastatic carcinoma of the colon or rectum.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	24/07/2025	
Other Decision Specified : National Cancer Medicines Advisory Group (NCMAG) Programme				
Web Link : https://www.healthcareimprovementscotland.scot/wp-content/uploads/2025/08/NCMAG123-Bevacizumab.pdf				
Bevacizumab				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
NCMAG124	Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the second-line treatment of adult patients with metastatic carcinoma of the colon or rectum.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	24/07/2025	
Other Decision Specified : National Cancer Medicines Advisory Group (NCMAG) Programme.				
Web Link : https://www.healthcareimprovementscotland.scot/wp-content/uploads/2025/07/NCMAG124-Advice-Document-july-2025.pdf				

selpercatinib hard capsules (Retsevmo®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2733	<p>as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).</p> <p>SMC restriction: patients who require systemic therapy who have not previously received systemic therapy. In an open-label, single-arm, phase I/II study in adult patients with RET fusion-positive thyroid cancer, 89% of patients who received selpercatinib achieved an objective response.</p>	Not routinely available as the ADTC is waiting for further advice from local clinical experts	07/07/2025	05/10/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9262/selpercatinib-retsevmo-final-june-2025-for-website.pdf				
osimertinib film-coated tablet (Tagrisso®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2736	in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.	Available in line with local or regional guidance	07/07/2025	18/03/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9260/osimertinib-tagrisso-final-june-2025-for-website.pdf				

amivantamab concentrate for solution for infusion (Rybrevant®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2758	in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.	Not routinely available as not recommended for use in NHS Scotland	07/07/2025	07/07/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9274/amivantamab-rybrevant-final-june-2025-for-website.pdf				
abaloparatide solution for injection in pre-filled pen (Eladynos®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2764	treatment of osteoporosis in postmenopausal women at increased risk of fracture. SMC restriction: postmenopausal people with osteoporosis at very high risk of fracture, assessed using a validated fracture risk assessment tool.	Available in line with local or regional guidance	07/07/2025	19/11/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9258/abaloparatide-eladynos-final-june-2025-amended-250625-for-website.pdf				

pembrolizumab concentrate for solution for infusion (Keytruda®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2767	in combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	07/07/2025	05/10/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9261/pembrolizumab-keytruda-final-june-2025-amended-110625-for-website.pdf				
fezolinetant film-coated tablets (Veoza®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2798	for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.	Not routinely available as not recommended for use in NHS Scotland	07/07/2025	07/07/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9275/fezolinetant-veoza-final-june-2025-for-website.pdf				

lecanemab concentrate for solution for infusion (Leqembi®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2811	for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoEε4) heterozygotes or non-carriers.	Not routinely available as not recommended for use in NHS Scotland	07/07/2025	07/07/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9259/lecanemab-leqembi-final-june-2025-for-website.pdf				